Hisamitsu Pharmaceutical Co (FSE:4530) 3-Year RORE % : 22.04% (As of Nov. 2025)


FSE:4530 Hisamitsu Pharmaceutical Co Inc FSE:4530
89 GF Score
Price 円3,975.00
GF Value 円3,237.07
View Full Analysis

What is Hisamitsu Pharmaceutical Co 3-Year RORE %?

Hisamitsu Pharmaceutical Co FSE:4530 89 3-Year RORE % is 22.04 as of Nov. 2025. GuruFocus rates FSE:4530 with a GF Score™ of 89/100 and a GF Value™ of 円3,237.07. Among 934 Drug Manufacturers companies, Hisamitsu Pharmaceutical Co ranks better than 69.81% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Hisamitsu Pharmaceutical Co's 3-Year RORE % for the quarter that ended in Nov. 2025 was 22.04%.

The industry rank for Hisamitsu Pharmaceutical Co's 3-Year RORE % or its related term are showing as below:

FSE:4530's 3-Year RORE % is ranked better than
69.81% of 934 companies
in the Drug Manufacturers industry
Industry Median: 3.09 vs FSE:4530: 22.04

Hisamitsu Pharmaceutical Co  (FSE:4530) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Hisamitsu Pharmaceutical Co 3-Year RORE % Related Terms


Hisamitsu Pharmaceutical Co 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co 3-Year RORE % Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -51.96 27.09 32.07 39.86 0.00

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.86 22.64 24.85 22.04 0.00

FSE:4530 vs ESPR, AMPH, ETON: 3-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hisamitsu Pharmaceutical Co 3-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Hisamitsu Pharmaceutical Co's 3-Year RORE % falls into.


FSE:4530
89GF Score
Hisamitsu Pharmaceutical Co Inc FSE:4530
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hisamitsu Pharmaceutical Co 3-Year RORE % Calculation

Hisamitsu Pharmaceutical Co's 3-Year RORE % for the quarter that ended in Nov. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 268.56-181.42 )/( 745.13-216 )
=87.14/529.13
=16.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Nov. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of 22.04 mean?
Hisamitsu Pharmaceutical Co (FSE:4530) has a 3-Year RORE % of 22.04 as of Nov. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Hisamitsu Pharmaceutical Co and its competitors. According to the industry distribution chart, Hisamitsu Pharmaceutical Co ranks #282 out of 934 companies in the Drug Manufacturers industry, placing it in the top 30.2%.
Is Hisamitsu Pharmaceutical Co's 3-Year RORE % too high?
Hisamitsu Pharmaceutical Co's current 3-Year RORE % is 22.04. The Drug Manufacturers industry median 3-Year RORE % is 3.09. Hisamitsu Pharmaceutical Co's value of 22.04 is 613.3% above this industry median. Based on the distribution chart, Hisamitsu Pharmaceutical Co ranks #282 out of 934 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's 3-Year RORE % compare to ESPR and AMPH?
According to the Drug Manufacturers industry distribution chart, Hisamitsu Pharmaceutical Co ranks #282 out of 934 companies for 3-Year RORE %. This puts Hisamitsu Pharmaceutical Co in the upper half of its industry. The industry median 3-Year RORE % is 3.09. Hisamitsu Pharmaceutical Co's value of 22.04 is 613.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.09, based on 934 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current 3-Year RORE % of 22.04 is 613.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Hisamitsu Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current 3-Year RORE % is 22.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current 3-Year RORE % of 22.04. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current 3-Year RORE % is 22.04 and 613.3% above the Drug Manufacturers industry median of 3.09. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current 3-Year RORE % is 22.04 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued. The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.

Key valuation signals for FSE:4530:

  • 3-Year RORE %: 22.04
  • GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
  • GF Score™: 89/100
  • Industry Position: 613.3% above the Drug Manufacturers median (#282 of 934)

No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hisamitsu Pharmaceutical Co Business Description

Other Exchanges HTSUY:USA
Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score

Get the complete analysis for FSE:4530

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円3,975.00
Price
円3,237.07
GF Value